Creative Medical Technology has filed a patent application for a type of stem cell technology that can regenerate failing ovaries, a method that can help women suffering from premature ovarian failure.
Creative Medical, a biotechnology company based in Phoenix, already manufactures an erectile dysfunction product that uses a patient’s own stem cells.
The company's ovary regeneration technology uses cells from a patient’s bone marrow that generate new blood vessels and creates a treatment that replaces scar tissue, the company said in a statement. The technology is targeted for women who experience accelerated menopause.
According to Creative Medical, one in 100 women under the age of 40 are affected by premature ovarian failure. There currently is no other effective treatment for the condition.
"Currently we are focusing on premature ovarian failure as an initial clinical indication," said Timothy Warbington, president and CEO of Creative Medical, in a statement. "Initial success in this indication will allow us to address aspects of the wider infertility market, which is estimated to reach over $20 billion annually."
Senior Writer
As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.